Oligometastatic prostate cancer (PCA) has increasingly been detected in the era of modern imaging studies such as choline-specific and prostate-specific membrane antigen (PSMA)-positron emission tomography and X-ray computed tomography (PET/CT). Recent evidence suggests that durable control is attainable with local treatment modalities such as salvage metastasectomy or stereotactic radiation therapy targeting oligometastases, either with or without the use of systemic therapy. The purpose of this article is to critically review the current findings on the indication, extent, and oncologic outcome of salvage lymphadenectomy (SLAD).
INTRODUCTION
Oligometastatic prostate cancer (PCA) has increasingly been considered as a unique clinical situation and challenge. Historically, distinctions with respect to lesser or greater extent of metastatic disease burden were not typically made, as patients were all treated with androgen deprivation therapy (ADT). Men with oligometastatic PCA were thus deemed incurable and treated systemically with ADT alongside those with widespread metastases. However, recent advances in imaging are identifying men with potentially isolated metastases and mounting evidence suggests that durable control is attainable with treatment modalities targeting oligometastases, either with or without the use of systemic therapy [1 && ,2,3]. Furthermore, a positive impact of radical prostatectomy and extended pelvic lymphadenectomy (LAD) on long-term oncological control has been shown for patients with lymph node metastases and a low lymph node density.
Such data support the hypothesis that oligometastatic PCA may represent a unique biological state with its own natural history requiring a distinct therapeutic approach [4] .
That said there are currently no clear-cut data or validated tools to guide optimal therapy for an individual patient. One school of thought is to consider isolated lesions on imaging as representing the only sites of disease, where local therapy is sufficient. The other viewpoint is that oligometastatic disease is most likely also associated with micrometastatic disease; therefore, concurrent systemic therapy with localized therapy should be considered the optimal treatment. In the latter case, disease at this stage is considered potentially curable as it is with adjuvant systemic therapy (in the form of ADT) to radiotherapy for high-risk localized disease or microscopic lymph node-positive disease following radical prostatectomy [5] [6] [7] [8] .
The purpose of this article is to provide the reader with the definition of oligometastatic PCA following local treatment of the primary, to summarize the role of positron emission tomography and X-ray computed tomography (PET/CT) with various radiotracers to identify oligometastatic lesions, to review oncological and functional outcome following salvage surgery, and to give recommendations with regard to the identification of the most ideal candidates for such a salvage procedure.
DEFINITION OF OLIGOMETASTATIC DISEASE
In their landmark article, Weichselbaum and Hellman [4] postulated the oligometastatic state of oncologic disease, in which patients may harbor a limited number of metastatic lesions. This state was viewed as existing on a continuum between localized and diffuse metastatic diseases, with oligometastic patients potentially receiving improved systemic control or even cure of their disease from treatment directed at these discrete metastatic foci. Indeed, there is increasing evidence on the molecular and genetic levels that oligometastatic disease is a distinct entity from diffusely metastatic disease, with the metastatic cells in oligometastases displaying a phenotype that lacks some of the elements necessary to bring about widespread metastases [1 && ]. This recognition results in a profoundly important change from the dogma that a small number of identifiable metastatic lesions necessarily connote widespread systemic disease and a stage of cancer only amenable to systemic chemotherapy.
To design a systematic approach to oligometastatic PCA, first and foremost a universally accepted definition is required. To that end, variability exists regarding what constitutes 'oligometastases', with cutoffs of both or less than three and or less than five lesions used in the literature, together with no rapid spread to more sites [3, 9] . Importantly, an accepted definition should require that targeted treatment of all metastatic lesions with surgery or radiotherapy is technically feasible. The rationale of oligometastases suggests that the resection of the primary site (if still in situ) and the surgical or radiotherapeutic ablation of the metastatic sites will result in a prolonged diseasefree or treatment-free interval. In addition, the definition of oligometastases by number of metastatic foci, standardization of imaging is paramount. Given the uncertainty of conventional imaging with bone scan and CT of the abdomen and the small pelvis to detect small volume metastases, newer imaging studies such as choline-specific or prostate-specific membrane antigen (PSMA)-PET/CT are involved in the routine decision-making process [10,11,12 & ].
DIAGNOSTIC APPROACH TO IDENTIFY OLIGOMETASTATIC LESIONS
Combined integrated PET/CT with radioactively labeled choline, derivatives thereof or radioactively labeled PSMA is currently recommended as a more sensitive imaging modality, but results of radiocholine PET/CT still leave room for improvement, especially at low serum levels of prostate-specific antigen (PSA) [13] [14] [15] [16] .
In choline PET studies, false-positive and falsenegative findings have been documented. An increased choline uptake has been reported in inflammatory tissue, probably related to active transport mechanisms and diffusion [17] [18] [19] [20] . Also, small bowel activity may mimic a positivity, mainly at the nodal level, explained by the high proliferation rate of intestinal mucosa [19] . However, the common use of integrated-modality PET/CT
KEY POINTS
Salvage pelvic LAD should be included in the therapeutic armamentarium of PCA patients with oligometastatic disease.
Salvage pelvic LAD should always be performed as an extended LAD.
Salvage LAD significantly prolongs median time until systemic treatment.
Patients with PSA less than 4 ng/ml, a PSA-doubling time more than 1 year, three or less visible lymph nodes, and the absence of retroperitoneal lymph node metastases appear to represent the ideal candidates for such a procedure.
scanning by adding morphologic information derived by CT scanning to those functional derived by PET scanning may be of help in most cases to clearly differentiate between physiologic and pathologic conditions [19] . False-negative findings may also occur, representing a major criticism at prostatectomy bed after radical prostatectomy. The detection rate of choline PET scanning for local recurrence as well as small neoplastic lymph nodes is limited, probably because of PET spatial resolution (approximately 5-6 mm), which does not allow the detection of small tumoral cell deposits at that site.
Although it has been shown that choline PET detection rates rise with increasing PSA values [11, [17] [18] [19] [20] , a PSA cutoff for properly referring patients to choline PET/CT imaging has not been established yet. In general, according to all the currently available data, it is suggested that the routine use of choline PET/CT scanning cannot be generally recommended for PSA values less than 1 ng/ml [10, 11] .
However, PSA value is not the sole factor influencing choline PET/CT results. In particular, it has been reported that PSA-doubling time (PSA-DT) in addition to PSA serum measurement is the most sensitive predictor of positive choline PET/CT scanning, and both measures should be taken into account when referring a patient for choline PET/ CT imaging. Giovacchini et al. [21] reported that the percentage of patients with positive choline PET/CT results was 27% for PSA-DT longer than 6 months, 61% for PSA-DT between 3 and 6 months, and 81% for PSA-DT shorter than 3 months. Winter et al. [22] reported a choline PET/CT detection rate of 20, 40, 48, and 60% in patients with PSA-DT longer than 6 months, between 4 and 6 months, between 2 and 4 months, and shorter than 2 months, respectively. They concluded that PSA-DT is to be considered in patients' selection for choline PET/CT scanning to reduce the number of false-negative findings and to increase the detection rate of disease in patients with early relapse and potentially curative disease [23] . We believe that as for the high incidence of positive findings, choline PET/CT imaging should be clinically recommended when PSA-DT is less than 3 months, also at low PSA serum values.
Recently, a novel radiotracer targeted at the PSMA was introduced [24 & ,25].
[68Ga]PSMA-HBED-CC (68Ga-PSMA) has shown a promising performance in initial studies and especially at very low PSA levels, 68Ga-PSMA seems to perform markedly better than one 8 F-fluoromethylcholine [26] . A positive 68Ga-PSMA PET/CT signal was described in lymph node metastases as small as 2.4 mm [27] , thus potentially significantly outperforming any form of dedicated morphologic imaging [28 && ].
Verburg et al. [12 & ] retrospectively studied the first 155 patients with recurrent PCA referred for [68Ga]PSMA-HBED-CC PET/CT. The relationship between the extent of disease determined by [68Ga]PSMA-HBED-CC-PET/CT and the important clinical measures PSA, PSA-DT, and Gleason score was evaluated.
PSMA-PET/CT was positive in 44, 79, and 89% of patients with PSA levels of or less 1, 1-2, and at least 2 ng/ml, respectively. Patients with high PSA levels showed higher rates of local prostate tumors (P < 0.001), and extrapelvic lymph node (P ¼ 0.037) and bone metastases (P ¼ 0.013). A shorter PSA-DT was significantly associated with pelvic lymph node (P ¼ 0.026), extrapelvic lymph node (P ¼ 0.001), bone (P < 0.001), and visceral (P ¼ 0.041) metastases. A high Gleason score was associated with more frequent pelvic lymph node metastases (P ¼ 0.039). In multivariate analysis, both PSA and PSA-DT were independent determinants of scan positivity and of extrapelvic lymph node metastases. PSA-DT was the only independent marker of bone metastases (P ¼ 0.001). Of 20 patients with a PSA-DT less than 6 months and a PSA 2 ng/ml or more, 19 (95%) had a positive scan and 12 (60%) had M1a disease. Of 14 patients with PSA less than 1 ng/ml and PSA-DT more than 6 months, only five (36%) had a positive scan and one (7%) had M1a disease.
In another study published by Eiber et al. [24 & ], even higher lesion detection rates for [68Ga]PSMA-HBED-CC PET/CT (96.8, 93.0, 72.7, and 57.9% for PSA levels of 2, 1 to <2, 0.5 to <1, and 0.2 to <0.5 ng/ml, respectively) were reported. However, the authors only examined a highly selected subset of PCA patients with biochemical recurrence (BCR) after radical prostatectomy, and therefore probably overestimated the scan positivity rate in patients with low PSA compared with those who received primary radiation therapy. Furthermore, Eiber et al. [24 & ] did not attempt to verify the scan results by means of histology.
To the best of our knowledge, there is only one retrospective study available, which compares the diagnostic value of choline-PET/CT versus PSMA-PET/CT based on surgical and pathohistological findings following salvage lymph node dissection (sLND) in relapsing patients with PCA [28 && ]. Thirty-eight patients had 18 FEC and 28 patients had 68 Ga-PSMA. We performed a pelvic and/or retroperitoneal LAD, if necessary supplemented by resection of locally recurrent lesions in accordance with imaging results. In 30/38 (78.9%) 18 FEC and 23/28 (82.1%) patients with 68 Ga-PSMA at least one focus of PCA was identified in postsurgical histology, leading to a per-patient positive predictive value (PPV) of 78.9% for 18 FEC and 82.1% for 68 Ga-PSMA. In 18 FEC and 68 Ga-PSMA patients, a total of 378 and 308 lymph nodes and local lesions were removed, respectively. For 18 
THE ROLE OF SALVAGE SURGERY IN RELAPSING OLIGOMETASTATIC PROSTATE CANCER
Although the resection of systemic metastases has been reported in case reports only and is beyond the scope of this article, salvage surgery for newly detected lymph node metastases in the small pelvis and/or the retroperitoneum in relapsing patients with PCA following previous local treatment, have been reported in various retrospective studies [22,28 && ,29-42] . Current standard treatment proposed by the guidelines for patients with BCR because of recurrence outside the prostatic bed remained unchanged over the last years, with ADT as a preferred systemic approach [10] . The lack of a curative approach and the significant long-term toxicity of ADT as the current standard treatment for the heterogeneous group of patients with PCA with BCR guided the focus on new therapeutic strategies such as imageguided sLND.
Studies on resection of lymph node metastases after local therapy
Local therapy of nodal oligometastatic relapse is a novel approach to patients with PCA with more and more studies being published in the literature. However, one has to consider that only retrospective, noncomparative studies on this issue have been published so that no final conclusions can be made with regard to the oncological efficacy of surgical or radiooncological salvage procedures.
As already being said, 68 Ga-PSMA-PET/CT or 18 C-choline PET/CT represents the imaging study of choice to identify patients with potential lymph node metastases. However, the majority of these studies did not focus on the correlation of positive PET signals with the final pathohistology. Recently, Passoni et al. [29] and Tilki et al. [30] assessed the accuracy of 18 F-choline-PET/CT in patients who underwent pelvic or retroperitoneal LND after detection of lymph node metastases.
Passoni et al. [29] evaluated 46 patients with BCR after radical prostatectomy and a single positive spot at [(11)C]choline PET/CT who underwent pelvic or pelvic and retroperitoneal lymph node dissection. Overall, 30 patients (65%) had positive lymph nodes at pathologic examination. Of these, only 16 (35%) had pathologically confirmed metastases in the same lymphatic region and 11 (24%) had involvement of one single lymph node. Conversely, 28 patients had positive lymph nodes in other areas and eight had no evidence of metastases. The overall PPV of PET/CT was 34.8 and 23.9% when exact concordance was defined according to the lymphatic landing site and single positive lymph node, respectively. The PPV ranged from 33.3 to 44.4% and from 17.9 to 28.6%, in men with and without ADT, respectively.
Tilki et al. [30] evaluated 58 patients with sLND after detection of lymph node recurrence by 18 Fcholine PET/CT. Six of them had additional extralymphatic findings in at least one extralymphatic location before sLND (prostatic bed in four and suspicion of a solitary bone metastasis in two patients). 60.4% of sLND were performed in the retroperitoneum or in the pelvic and retroperitoneal area. Mean PSA at sLND was 9.8 ng/ml, 47% of patients received ADT before sLND and the mean number of LNs removed was 18.6. cBR developed in 22.4% of patients but only one patient, representing 7.7% of those with cBR, remained BCR-free throughout the whole follow-up leading to a 5-year BCR-free survival rate of 0%. Median follow-up was 39 months and the 5-year clinical recurrence-free survival rate was 42.4% in patients with cBR and 32.6% in patients without cBR, respectively. The 5-year cancer-specific survival (CSS) rate was 71.1%.
Both studies point to the fact that the accuracy and reliability of choline-PET/CT in the detection of a single lymph node metastasis is poor and that a considerable rate of false-positive and false-negative results have to be taken into consideration.
To the best of our knowledge, there is only one retrospective study available, which compares the diagnostic value of choline-PET/CT versus PSMA-PET/CT based on surgical and pathohistological findings following sLND in relapsing patients with PCA [28 && ]. Thirty-eight patients had 18 FEC and 28 patients had 68 Ga-PSMA before a pelvic and/or retroperitoneal LAD. In 30/38 (78.9%) 18 FEC and 23/28 (82.1%) 68 Ga-PSMA patients, at least one focus of PCA was identified in postsurgical histology, leading to a per-patient PPV of 78.9% for 18 FEC and 82.1% for 68 Ga-PSMA. In patients with 18 FEC and 68 Ga-PSMA, a total of 378 and 308 lymph nodes and local lesions were removed, respectively. For 18 FEC and for 68 Ga-PSMA, the respective sensitivity (95% confidence interval) was 71.2% (64.5-79.6%) and 86.9% (75.8-94.2%), specificity was 86.9% (82.3-90.6%) and 93.1% (89.2-95.9%), PPV was 67.3% (57.7-75.9%) and 75.7% (64.0-98.5%), NPV was 88.8% (84.4-92.3%) and 96.6% (93.5-98.5%), and accuracy was 82.5% (78.3-86.8%) and 91.9% (88.7-95.1%). Based on the data of this series, the diagnostic accuracy of 68 Ga-PSMA-PET/CT was significantly superior to choline-PET/CT and it should be the preferred the diagnostic method of choice if available.
EXTENT OF SURGERY
Based on the data of the studies mentioned above, it appears to be obvious that the salvage treatment should be directed to the suspicious lesion alone but that an extended lymph node dissection should be performed especially in patients who had undergone radical prostatectomy with suboptimal anatomical extent of their previous LND. Therefore, a bilateral extended pelvic lymph node dissection should be performed in patients with PSMA-positive lymph nodes in order to compensate for the diagnostic inaccuracy of the imaging modalities.
The question still remains unanswered if LND should be extended to the retroperitoneal lymph nodes if positive signals are detected. If retroperitoneal lymph node dissection (RPLND) is performed, it needs to be performed in a bilateral radical template covering all lymph nodes between the renal vessels and the aortic bifurcation, between the paracaval and paraaortic region including the interaotocaval lymph nodes. When discussing the issue of RPLND in the context of relapsing PCA, one also has to consider the worse prognosis of patients with retroperitoneal lymph nodes. One study of sLND reported 8-year clinical recurrence-free survival of 22% for retroperitoneal nodal involvement versus 69% without retroperitoneal disease [31] . Another study noted 5-year clinical recurrence-free survival of 11% with retroperitoneal involvement versus 53% without retroperitoneal disease [31] . These data underline that the majority of patients with retroperitoneal disease do not only relapse, but relapse early so that the benefit of surgery is quite limited. We need to develop reliable predictive markers of early progression before salvage RPLND can be recommended as a routine procedure.
ONCOLOGICAL OUTCOME IN PATIENTS UNDERGOING SALVAGE LYMPH NODE DISSECTION
As mentioned above, the goals of salvage LND is to at least prolonging biochemical or clinical relapsefree survival. Currently, there are no data available demonstrating a cancer-specific or overall survival benefit.
In most studies, biochemical response was defined as PSA less than 0.2 ng/ml at 40 days postoperatively [22,28 && ,29-41] . In one of the largest studies, Rigatti et al. [32] prospectively evaluated the outcome of 72 patients who underwent pelvic or retroperitoneal salvage LND for a nodal disorder on a choline-PET/CT. The study was recently updated by Suardi et al. [31] who focused on patients with a follow-up of at least 5 years. In the first report by Rigatti et al. [32] , mean PSA at sLND was 3.73 ng/ml and 55.5% of patients received ADT before surgery. 77.8% of sLND involved pelvic plus retroperitoneal area with a median number of 29 LNs removed. The cBR rate was 56.9% 40 days postoperatively but 65.3% of patients received adjuvant ADT after sLND. At a median follow-up of 39.8 months, 5-year BCR-free survival rate was 19%, 48.6% of patients experienced clinical recurrence, and the 5-year CSS rate was 75%. In the updated series reported by Suardi et al. [31] , 35 of the analyzed 52 patients (59.3%) had cBR after surgery and the 5-year and 8-year BCR-free survival rates among these patients were 29.4 and 22.1%, respectively. The 5-year and 8-year clinical recurrence-free survival rates were 52.0 and 38.2% and the 5-year and 8-year CSS rates were 89.1 and 80.6%, respectively. The authors could identify PSA level at sLND [<4 ng/ml versus >4 ng/ml; hazard ratio (HR) 2.13; 95% CI ¼ 1.05-4.32; P ¼ 0.03], presence of lymph node metastases at time of radical prostatectomy (HR 1.12; 95% CI, 0.52-2.41), and retroperitoneal versus pelvic lymph node metastases (HR 2.92; 95% CI ¼ 1.4-6.11; P ¼ 0.004) associated with clinical relapse. PSA at surgery (<4 ng/ml versus >4 ng/ml; HR 0.13; 95% CI ¼ 0.04-0.5; P ¼ 0.003), time to biochemical relapse after radical prostatectomy (< versus >24 months; HR 7.07; 95% CI, 1.98-25.17; P ¼ 0.003), and presence of lymph node metastases at time of initial radical prostatectomy (HR 0.22; 95% CI ¼ 0.06-0.86; P ¼ 0.03) were significant predictors associated with a high probability of complete biochemical response (cBR) postoperatively. However, cBR was associated with a significantly improved 5-year clinical recurrence-free survival of 54 versus 18%.
Jilg et al. [32] examined 47 patients who underwent sLND because of nodal recurrence of PCA based on evidence of 11 C-choline/ 18 F-choline PET/ CT [10] . In contrast to our cohort and all other studies published to date, 27 patients received adjuvant radiotherapy of regions with histopathological confirmation of lymph node metastases and six patients had additional evidence of local PCA recurrence. Mean (median) PSA at sLND was 11.1 ng/ml (5.2 ng/ml) and 78.7% of patients received ADT before sLND. In only 54% of cases, sLND was limited to the pelvic area and the median number of lymph nodes removed was 12. cBR was achieved in 46% of patients and during a median follow-up of 35.5 months, the 5-year BCR-free survival, clinical recurrence-free survival, and CSS rates were 8.7, 25.6, and 77.7%, respectively. Sixty-five percent of patients received ADT after sLND because of recurrence. The authors could identify Gleason score 8-10 at radical prostatectomy, presence of positive retroperitoneal LNs, and a lack of cBR as independent predictors of clinical recurrence on multivariate analysis [10] .
In the series of Porres et al. [34] , 87 patients with BCR and positive lymph nodes on either 18 F-choline or 68 Ga-PSMA-PET/CT underwent salvage LAD after primary treatment of PCA. Mean age of patients and mean PSA at sLND was 66.7 years and 2.63 ng/ml, respectively. 96.5% of sLND were limited to the pelvic area. 57.9% of patients underwent adjuvant/salvage radiation therapy after PT and 18.4% received ADT prior to sLND. cBR, defined as a postoperative PSA level less than 0.2 ng/ml, was diagnosed in 27.5% of patients and incomplete biochemical response in 40.6%. 62.2% of patients remained without ADT at follow-up. With a median follow-up of 21 months (1-75 months) cancer-specific mortality rate was 3.7%. Three-year BCRfree, systemic therapy-free and clinical recurrencefree survival rates for patients with cBR were 69.3, 77.0, and 75%, respectively.
The largest U.S. study of sLND was published by Karnes et al. [35] and included 52 patients. During a median follow-up of 20 months 57.7% of patients had PSA remain less than 0.2 ng/ml, and 3-year BCRfree, CR-free survival and CSS rates were 45.5, 46.9, and 92.5%, respectively. 78.8% of patients had undergone some form of second-line therapy after radical prostatectomy, including ADT, radiation therapy, chemotherapy or immunotherapy and 82.7% received adjuvant ADT immediately after sLND [28 && ]. The results of other studies with smaller patient numbers are summarized in Table 1 [22, [36] [37] [38] [39] [40] [41] . In summary, the mean follow-up varies between 14 and 81 months, the cBR varies between 40 and 59% and the 5-year biochemical relapse-free survival varies between 9% and 40%. These data highlight the fact that we need to identify reliable parameters associated with long-term response or we need to identify clinically useful adjuvant therapeutic measures to improve the long-term outcome of our patients.
In the context, Rischke et al. [41] evaluated the potential benefit of adjuvant radiation therapy in 93 patients with exclusively nodal metastases of whom 46 underwent surgery and 47 underwent surgery and adjuvant radiation therapy to areas with histologically proven lymph node metastases. ART resulted in significantly improved 5-year relapsefree survival rate within the treated region of 70.7 versus 26.3% (P < 0.0001) in the surgery only group. 
COMPLICATIONS ASSOCIATED WITH SALVAGE LYMPHADENECTOMY
As mentioned earlier, treatment-associated complications should be minimal in a therapeutic concept which still has a very individual and experimental scientific background associated with a low level of evidence.
In recently published review papers, Ost et al. [43] and ploussard et al. [44 & ] summarized the complications associated with salvage LAD. Most interestingly, only the minority of studies reported complications according to the Clavien-Dindo classification system. The majority of complications were minor or less 2 complications in about 10-20% such as fever, wound dehiscence, deep venous thrombosis, paralytic ileus. However, the frequency of complications, for example for paralytic ileus varied from 0 to 20% depending on the series. Significant grade 3a or 3b complications occurred in up to 10 and 1%, respectively. In our own series of 87 patients [33] , three (9.2%) patients developed grade 3a complications (one intraoperative obturator nerve lesion, five lymphoceles that required surgical drainage and two patients with obstructive ileus). In another paper including 17 patients grade or less two were observed in one (6%) patient and grade 3a/b complications were reported in three (18%) patients [45] .
Based on these data, salvage LAD represents a well tolerated procedure with a low-toxicity profile.
SELECTION OF PATIENTS FOR SALVAGE LYMPHADENECTOMY
Based on the limited data available and the low level of scientific evidence, it is quite difficult to identify reliable predictive and prognostic parameters associated with long-term oncological control. However, it appears evident that salvage LND might be beneficial in only a limited number of patients.
Various groups have attempted to define several preoperative risk factors which might be helpful when counselling patients ( Table 2 ). Rigatti et al. [32] identified various preoperative parameters to be associated with a higher 5-year clinical relapse-free survival: PSA less than 4 versus 4 ng/ml or more (48 versus 13%, P ¼ 0.004); absence of retroperitoneal lymph nodes (53 versus 11%, P < 0.001). Both markers were reproduced in univariate and multivariate analysis. Jilg et al. [33] identified a preoperative Gleason score 8-10 as significant predictor of clinical relapse (HR ¼ 3.5, P ¼ 0.039), whereas the presence of retroperitoneal lymph node metastases (HR ¼ 3.76, P ¼ 0.021) and lack of postoperative biochemical response (HR ¼ 4.0, P ¼ 0.031) were significant markers associated with early clinical progression. In our own series [34] , Gleason score 8-10 at time of PET/CT (OR 0.06, P ¼ 0.009) was associated with a significantly higher risk of not achieving cBR, which was the only independent predictor of BCR (HR ¼ 7.05, P ¼ 0.001).
CONCLUSION
Overall, emerging data suggest that surgery may represent an important therapeutic modality in the management of oligometastatic PCA. Ultimately, optimal patient selection is critical. sLND is likewise associated with favorable oncologic outcomes for oligometastatic nodal recurrence after local therapy. Retroperitoneal lymph node metastases are associated with a significantly higher risk of biochemical and clinical relapse as compared to pelvic lymph node metastases. Prospective studies will further inform these issues and will also inform whether it can be used alone or in combination with systemic therapy.
A number of unanswered questions remain relevant to the discussion of oligometastatic PCA. It clearly has a longer natural history and presumably has a more indolent biology, most of the time. That said, it is unknown at this time whether there will be a higher incidence of more advanced and denovo metastatic disease with decreased PSA screening in United States. If this is the case, there will be more patients with metastatic disease and an even greater need at the public health level to improve therapy for metastatic hormone sensitive PCA. Related to diagnosis is what, if any, impact the new imaging modalities will have on the course of disease. For example, are the patients identified with oligometastases by such highly sensitive tests radiotherapy to the metastatic lesion alone, with less systemic effects, sufficient or is the patient best treated with ADT plus radiotherapy? Moreover, there is a paucity of data regarding whether the total number and location of oligometastases (by standard CT and radionuclide bone scan imaging) is prognostically important. Identifying the patients most likely to benefit from treatment is needed. As detailed above, treatment of oligometastases with focal ablative therapies appears promising but requires further validation in prospective studies before it can be recommended as standard of care [36] . Data supporting treatment of lymph node only recurrence are also limited, although a recent review suggested it may confer a therapeutic benefit [35] . When designing such prospective studies, there is differing opinion whether delay in requiring ADT, overall survival, or both should be the primary endpoint.
Ultimately, the decision regarding when, and how, to treat men with oligometastatic PCA requires an assessment of the competing risks of burden of therapy versus those of progressive disease and subsequent therapies. Such an evaluation requires incorporating factors such as symptoms, comorbidities and life expectancy. Specifically, competing risks of death are very relevant in patients with oligometastatic hormone-sensitive PCA. Moreover, actively engaging patients in the therapeutic discussion, defining goals of care and enabling shared decision-making are all required. Further prospective, randomized data are necessary to better characterize the nature of oligometastatic PCA and define the role and value of therapies in this state. These trials should take into account the gaps in knowledge described herein, and help to address the most pressing quandaries facing clinicians and patients today.
